This phenomenon may explain the failures of clinical trial focusing on anti-endotoxin agents [5], where neither human antiserum to endotoxin nor monoclonal IgM antibodies that inactivates endotoxin could significantly improve survival in sepsis. This evidence concerns the gene CD40LG and Sepsis.